Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People whose ability to carry out daily activities falls within a certain range, meaning they are fully active or have some limitations but are still able to care for themselves (confirm with trial site)
- People who have been diagnosed with pancreatic cancer that has been confirmed by tissue testing and has either spread to other parts of the body or cannot be surgically removed
- People receiving first-line palliative chemotherapy (treatment aimed at managing the disease rather than curing it) using platinum-based or gemcitabine-based drugs, or those receiving a specific combination called nal-Irinotecan/5-FU/Leucovorin — including people who previously had chemotherapy before or after surgery
- People who have signed a consent form to participate (for patients enrolled going forward); for patients whose data is being reviewed from the past, a signed consent form is not required
Who may not be able to join:
- People with locally advanced pancreatic cancer that could potentially be surgically removed and who are not receiving palliative chemotherapy
- People with locally advanced pancreatic cancer that sits on the borderline of being surgically removable and who are not receiving palliative chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jakob Riedl, Priv.Doz. Dr., Medical University of Graz
Phone: +43 316 385 13115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.